NHSN
NATIONAL HEALTHCARE SAFETY NETWORK

March 2026

Respiratory Pathogens and Vaccination Module: RPV Summary - Residents Guidance Document

This document provides instructions for reporting the weekly Resident Respiratory Pathogens and Vaccination (RPV) Summary form. Within this guidance document, a combination of instructions and screen shots are used to illustrate the steps for navigating and reporting these data through manual data entry in the NHSN application. In addition to this guidance document, users are encouraged to use the RP Summary Residents TOI.

Instructions

Select Module – After logging into the LTCF NHSN Component, there are two options to access the reporting screen. Select "Respiratory Pathogens and Vaccination > RPV – Residents" or "RPV Summary" from the blue menu bar to navigate to the Respiratory Pathogens and Vaccination Summary Data calendar view for surveillance reporting.



Select Reporting Week – From the weekly view page, select the week for which data will be reported.

Respiratory Pathogens and Vaccination (RPV) Summary Data

Click a cell to begin entering data for the week which counts are reported.

Reporting of medical events or health problems that occur after vaccination (possible side effects) is encouraged, even if you are not sure they are the result of vaccination, at https://vaers.hhs.gov/reportevent.html.

26 January 2026 - 08 March 2026 | Record Complete | Record Incomplete | Record Partially Complete

Weekly RPV Calendar

01/26/2026 (Monday) - 02/01/2026 (Sunday)
- COVID-19: HCP
- RPV: Residents

02/02/2026 (Monday) - 02/08/2026 (Sunday)
- COVID-19: HCP
- RPV: Residents

02/09/2026 (Monday) - 02/15/2026 (Sunday)
- COVID-19: HCP
- RPV: Residents

Select Tab – Select "RPV – Residents" where the data will be entered.

Add Vaccine Data

COVID-19 Vaccine: HCP | RPV: Residents

Weekly Respiratory Pathogen and Vaccination Summary for Residents of Long-Term Care Facilities

Step 1: Enter the number of residents staying in the facility for at least 1 day during the week of data collection.

1. *Number of residents staying in this facility for at least 1 day during the week of data collection

Required

Step 2: Cumulative Vaccination Coverage – Enter the number of residents who are up to date with COVID-19 vaccination and the number of residents who have received Influenza (for the appropriate season) and RSV vaccines.

Please refer to the COVID-19 Key Terms and Recommendations document to determine how many residents are considered up to date with COVID-19 vaccines. Please refer to the Influenza and RSV Key Terms and Recommendations document to ensure correct reporting of influenza and RSV vaccination status.

Cumulat[illegible]cination Coverage	
2. Resident Vaccination: Among residents in Question #1:	
2a. *Number of residents who are up to date with COVID-19 vaccines	
2b. *Number of residents who have received this season's annual influenza vaccine (2024-2025)	
2c. *Number of residents who have received RSV vaccine	

Step 3: Resident Cases (Positive Tests) and Vaccination Status – For 3a, enter the number of residents who had a newly positive SARS-CoV-2 viral test during this reporting week. For 3ai, out of the number of residents reported in 3a, enter the number of those residents who are also up to date with COVID-19 vaccines.

- **Important:** Refer to the COVID-19 Key Terms and Recommendations to determine which resides would be considered up to date. Residents must have received the most recent vaccine at least 14 days or more before the positive test result to be included in 3ai.

For 3b, enter the number of residents who had a newly positive Influenza viral test during this reporting week. Then out of the number reported for 3b, enter the number of residents who have received this season's flu vaccine 14 days or more before the positive test for question 3bi. For 3c, enter the number of residents who had a newly positive RSV viral test during this reporting week. Then out of the number reported for 3c, enter the number of residents who have received the RSV vaccine 14 days or more before the positive test for question 3ci.

- **Important:** Refer to the Influenza and RSV Key Terms and Recommendations document to aid in making this determination. Residents must have received the most recent vaccine at least 14 days or more before the positive test result.

New Resident Cases (Positive Tests) and Hospitalizations During the Week of Data Collection	
3. Resident Cases (Positive Tests):	
3a. ***COVID-19:** Residents with a Positive Test	
3ai. **Number of residents in Question #3a who received the up to date COVID-19 vaccine 14 days or more before the positive test	
3b. ***Influenza:** Residents with a Positive Test	
3bi. **Number of residents in Question #3b who received this season's annual influenza vaccine (2024-2025) 14 days or more before the positive test	
3c. ***RSV:** Residents with a Positive Test	
3ci. **Number of residents in Question #3c who received RSV vaccine 14 days or more before the positive test	

Step 4: Residents Hospitalized with a Positive Test – For 4a, enter the number of residents who were admitted to the hospital during this reporting week, and had a positive COVID-19 test in the 10 days prior to the admission. Then out of the number of residents entered in 4a, enter the number of those residents who are considered up to date with COVID-19 vaccine for question 4ai.

- **Important:** Refer to the COVID-19 Key Terms and Recommendations to determine which residents would be considered up to date for this count, residents must have received the most recent vaccine at least 14 days or more before the positive test result.

For 4b, enter the number of residents who were admitted to the hospital during the reporting week and had a newly positive Influenza viral test in the 10 days prior to the admission. Then out of the number reported for 4b, enter the number of residents who have received this season's flu vaccine 14 days or more before the positive test for question 4bi. For 4c, enter the number of residents who were admitted to the hospital during the reporting week and had a newly positive RSV viral test in the 10 days prior to the admission. Then out of the number reported for 4c, enter the number of residents who have received the RSV vaccine 14 days or more before the positive test for question 4ci.

- **Important:** Refer to the Influenza and RSV Key Terms and Recommendations document to determine which residents would be considered up to date for this count, residents must have received the most recent vaccine at least 14 days or more before the positive test result

4. Residents Hospitalized with a Positive Test:	
4a. *COVID-19: Residents hospitalized this week, and had a positive test in the last 10 days	
4ai. **Number of residents in Question #4a who received the up to date COVID-19 vaccine 14 days or more before the positive test	
4b. *Influenza: Residents hospitalized this week, and had a positive test in the last 10 days	
4bi. **Number of residents in Question #4b who received this season's annual influenza vaccine (2024-2025) 14 days or more before the positive test	
4c. *RSV: Residents hospitalized this week, and had a positive test in the last 10 days	
4ci. **Number of residents in Question #4c who received RSV vaccine 14 days or more before the positive test	

Determining how to include a resident in question 4 (4a, 4ai, 4b, 4bi, 4c, 4ci).

- Residents hospitalized with a positive test
  - First determine how many residents were admitted to the hospital during this reporting week.
  - Once that number has been calculated, determine how many of those residents also had a positive test in the 10 days prior to the admission.
    - For example: Mr. Smith was admitted to the hospital on Wednesday of this week. He had a positive COVID-19 test the Friday before (5 days prior to the admission). Mr. Smith would be included in this count.
- Residents hospitalized with a positive test and vaccination status
  - Then determine the vaccination status of the residents who have been included in the hospitalizations count.
    - Out of the number reported for the hospitalizations count, determine how many of those residents received vaccine to be considered up to date or vaccinated.
    - Once that count has been calculated, determine who received vaccine at least 14 days prior to the positive test.
    - For example: Mr. Smith who was included in the hospitalizations count, received the updated COVID-19 vaccine 1 month ago. Since he received the vaccine 14 days or more before the positive test (he had a positive test the week before he was admitted to the hospital) he would be included in the count.

OPTIONAL Step 5: Residents who Received Therapeutics – If a facility chooses to enter data for question #5, they must complete all fields.

For 5a, if a user wishes to complete the form and notate no therapeutics were administered during the week of data collection, they can select the check box. By clicking the check box, zeros will populate for questions 5b, 5c, and 5d.

5. **Residents who Received Therapeutics:**	
5a. **Did not administer any therapeutics**	☑

If the user wishes to complete the form and therapeutics were administered, then questions 5b, 5c, and 5d must be completed. For 5b, enter the total number of residents who have received treatment for COVID-19 during the week of data collection. If 5b is greater than zero, then you must answer questions 5bi, 5bii, and 5biii and the value must be equal to 5b.

For 5c, enter the total number of residents who have received treatment for influenza during the week of data collection. If 5c is greater than zero, then you must answer questions 5ci, 5cii, 5ciii, and 5civ. If 5c is greater than zero, then you must answer questions 5ci, 5cii, 5ciii, and 5civ and the value must be equal to 5c.

For 5d, enter the total number of residents who have received treatment for RSV during the week of data collection. If 5d is greater than zero, then you must answer questions 5di, 5dii, 5diii, and 5div. If 5d is greater than zero, then you must answer questions 5di, 5dii, 5diii, and 5div and the value must be equal to 5d.

Therapeutics Administered to Residents During the Week of Data Collection (Optional Reporting: These data are NOT required.) **For each therapeutic listed, enter number of residents who received the therapeutic(s) at this facility during the reporting week**	
5. **Residents who Received Therapeutics:**	
5a. **Did not administer any therapeutics**	☐
5b. **COVID-19:** Number of residents who have received treatment during the week of data collection	
5bi. Nirmatrelvir (Paxlovid)	
5bii. Remdesivir (Veklury)	
5biii. Molnupiravir (Lagevrio)	
5c. **Influenza:** Number of residents who have received treatment during the week of data collection	
5ci. Oseltamivir (Tamiflu)	
5cii. Zanamivir	
5ciii. Peramivir (Rapivab)	
5civ. Baloxavir Marboxil (Xofluza)	
5d. **RSV:** Number of residents who have received treatment during the week of data collection	
5di. Ribavirin	
5dii. Palivizumab (Synagis)	
5diii. Nirsevimab (Beyfortus)	
5div. Clesrovimab (Enflonsia)	

Step 6: Review data and Submit form – The screen shot below is an example of data entry of **required** fields.

COVID-19 Vaccine: HCP | RPV: Residents

Weekly Respiratory Pathogens and Vaccination Summary for Residents of Long-Term Care Facilities

Date Created (UTC):
Date Completed (UTC):
*Facility ID:
Facility CCN #:
*Week of data collection (Monday - Sunday):
*Date Last Modified (UTC):
Flu/ Respiratory Virus Season: 2025-2026

1. *Number of residents staying in this facility for at least 1 day during the week of data collection	100
Cumulative Vaccination Coverage	
2. **Resident Vaccination: Among residents in Question #1:**	
2a. *Number of residents who are up to date with COVID-19 vaccines	50
2b. *Number of residents who have received this season's annual influenza vaccine **(2025-2026)**	45
2c. *Number of residents who have received RSV vaccine	35
New Resident Cases (Positive Tests) and Hospitalizations During the Week of Data Collection	
3. **Resident Cases (Positive Tests):**	
3a. ***COVID-19:** Residents with a Positive Test	5
3ai. **Number of residents in Question #3a who received the up to date COVID-19 vaccine 14 days or more before the positive test	1
3b. ***Influenza:** Residents with a Positive Test	3
3bi. **Number of residents in Question #3b who received this season's annual influenza vaccine **(2025-2026)** 14 days or more before the positive test	2
3c. ***RSV:** Residents with a Positive Test	0
3ci. **Number of residents in Question #3c who received RSV vaccine 14 days or more before the positive test	0
4. **Residents Hospitalized with a Positive Test:**	
4a. ***COVID-19:** Residents hospitalized this week, and had a positive test in the last 10 days	0
4ai. **Number of residents in Question #4a who received the up to date COVID-19 vaccine 14 days or more before the positive test	0
4b. ***Influenza:** Residents hospitalized this week, and had a positive test in the last 10 days	1
4bi. **Number of residents in Question #4b who received this season's annual influenza vaccine **(2025-2026)** 14 days or more before the positive test	1
4c. ***RSV:** Residents hospitalized this week, and had a positive test in the last 10 days	0
4ci. **Number of residents in Question #4c who received RSV vaccine 14 days or more before the positive test	0
Therapeutics Administered to Residents During the Week of Data Collection (Optional Reporting: These data are NOT required.)	
For each therapeutic listed, enter number of residents who received the therapeutic(s) at this facility during the reporting week	
5. **Residents who Received Therapeutics:**	
5a. **Did not administer any therapeutics**	☐
5b. **COVID-19:** Number of residents who have received treatment during the week of data collection	
5bi. Nirmatrelvir (Paxlovid)	
5bii. Remdesivir (Veklury)	
5biii. Molnupiravir (Lagevrio)	
5c. **Influenza:** Number of residents who have received treatment during the week of data collection	
5ci. Oseltamivir (Tamiflu)	
5cii. Zanamivir	
5ciii. Peramivir (Rapivab)	
5civ. Baloxavir Marboxil (Xofluza)	
5d. **RSV:** Number of residents who have received treatment during the week of data collection	
5di. Ribavirin	
5dii. Palivizumab (Synagis)	
5diii. Nirsevimab (Beyfortus)	
5div. Clesrovimab (Enflonsia)	

Save | Cancel